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Title: The relationship between gluten free diet adherence and depressive symptoms in adults 
with coeliac disease: A systematic review with meta-analysis 
 
ABSTRACT 
Purpose: Depressive symptoms are common in patients with coeliac disease (CD) and may 
represent a barrier to gluten free diet (GFD) adherence. The aims of this meta-analysis were: 
(1) to synthesise the evidence on the relationship between depression or depressive symptoms 
and degree of adherence to a GFD in patients with CD who are already attempting a GFD 
(i.e., post-diagnosis and onset of GFD), and (2) to summarise the direction of causation of 
any observed relationship.  
Methods: A random effects meta-analysis of 8 cross-sectional studies (N=1644) was 
conducted. Included studies measured self-reported depressive symptoms and GFD 
adherence using either a dietitian interview or validated self-report questionnaire that 
considered unintentional gluten consumption. 
Results: There was a moderate association between poorer GFD adherence and greater 
depressive symptoms (r=0.398, 95% CI=0.321-0.469), with marked heterogeneity in the 
effects (I2=66.8%). A sensitivity analysis excluding studies with a moderate/high (k=1) or 
unclear risk of bias (k=1) did not change the results.  
Conclusion: The low number of studies meeting inclusion criteria limits the strength of the 
conclusions. Available evidence suggests there is an association between poorer GFD 
adherence and self-reported depressive symptoms; however, studies using longitudinal and 
prospective designs, and reliable measures, particularly for adherence, are needed to confirm 
this association. The direction of causation between depression and adherence remains 
unclear.  
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INTRODUCTION 
Coeliac disease (CD) is a chronic autoimmune condition involving intolerance to 
dietary gluten, for which clinical management involves lifelong strict adherence to a gluten 
free diet (GFD; Green & Cellier, 2007). Undiagnosed or poorly managed, CD is associated 
with gastrointestinal and malabsorption symptoms and increased risk of long-term health 
complications, including intestinal cancers, osteoporosis, and infertility (Green & Cellier, 
2007; Green & Jabri, 2003). Depression is also often cited as a symptom of undiagnosed CD 
(Jackson, Eaton, Cascella, Fasano, & Kelly, 2012), and clinically diagnosed depression 
and/or depressive symptoms (typically collapsed in reviews) appear to occur with greater 
frequency and/or severity in CD than healthy samples (Smith & Gerdes, 2012; Zingone et al., 
2015).  
Meta-analyses conducted in other chronic illnesses (e.g., diabetes) have found 
significant associations between depression and non-adherence to medication and other 
treatment components (e.g., diet and physical activity recommendations; DiMatteo, Lepper, 
& Croghan, 2000; Gonzalez et al., 2008; Grenard et al., 2011), with depressed patients being 
1.76-to-3 times less likely to adhere to medical treatment recommendations than non-
depressed patients (DiMatteo et al., 2000; Grenard et al., 2011). Further, reduced treatment 
adherence is one mechanism via which the link between depression and many preventable 
chronic illnesses may be explained (Katon, 2011). That is, depression may act as a barrier to 
good self-care (e.g., resulting in poor diet and physical inactivity – or in the case of CD, poor 
management of the GFD) via deficits in energy and memory, which leads to the development 
of risk factors such as obesity, which prompt or exacerbate the symptoms of chronic illness 
(e.g., diabetes), and, in turn, become further barriers to good adherence (Katon, 2011).  
The literature on a comparable relationship between depression and GFD adherence 
in CD patients has yet to be synthesised, with existing reviews on the incidence of depression 
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in CD (Smith & Gerdes, 2012; Zingone et al., 2015) being methodologically unable to 
answer the more specific question regarding GFD adherence. Firstly, evidence for the 
depression-adherence association comes primarily from studies assessing differences in 
depression between newly-diagnosed patients and those already being managed on a GFD, 
without assessment of the adequacy of dietary adherence in the established gluten free 
patients. Secondly, amongst studies that have specifically measured GFD adherence, 
conclusions have been drawn without due consideration of the impact of unreliable 
measurement of GFD adherence. Finally, the absence of a healthy control group (inclusion 
criteria for both previous reviews) meant that many studies relevant to answering this more 
specific question were excluded.   
Debate exists on the optimal way to measure GFD adherence (Leffler et al., 2007; 
Ludvigsson et al., 2014; Vahedi et al., 2003), resulting in large variation in definitions and 
measurement across studies (Hall, Rubin, & Charnock, 2009). Intentional gluten 
consumption in patients with CD appears rare, with unintentional non-adherence (e.g., due to 
cross contamination or errors in label reading) representing the most common reason for 
lapsing from the GFD (Hall, Rubin, & Charnock, 2013; Sainsbury et al., 2013a). Commonly 
used adherence measures, such as single-item self-report questions (e.g., ‘how strictly do you 
adhere to your GFD?’ with Likert or visual analogue response scales from ‘not at all’ to ‘very 
strictly’) and serological analyses, are unreliable at detecting incomplete adherence, 
particularly with increased time on a GFD (Leffler et al., 2007). These methods also do not 
correlate well with dietitian-rated assessments (Fera, Cascio, Angelini, Martini, & Guidetti, 
2003; Leffler et al., 2007; Vahedi et al., 2003), the method currently deemed the ‘gold 
standard’ (Leffler et al., 2007; Ludvigsson et al., 2014). The dietitian assessment involves 
completion of a 3-day food record (prior to the session), a food ingredient quiz, and a 
dynamic clinical interview in which an experienced dietitian evaluates the food record with 
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the patient to identify any gluten consumption or sources of cross-contamination that may 
compromise adherence. Regarding simple self-report measures, the discrepancy with dietitian 
assessments probably results from their failure to consider unintentional gluten consumption, 
which, by definition, occurs outside of conscious awareness, as well as inaccuracies in patient 
understanding and knowledge of the GFD (Leffler et al., 2007; Silvester, Weiten, Graff, 
Walker, & Duerksen, 2016). Serological results adequately indicate gluten-related damage at 
diagnosis; however, once on a GFD, produce frequent false negative results in known 
partially adherent individuals (Leffler et al., 2007; Vahedi et al., 2003). 
To fill the gap in the availability of valid and reliable tools for assessing GFD 
adherence and provide a feasible measure within the research context, several questionnaires 
that do account for unintentional gluten exposure have been designed. These include the 
Coeliac Dietary Adherence Test (CDAT; Leffler et al., 2009), which was developed in 
consultation with an expert panel, and has demonstrated psychometric properties. The CDAT 
has acceptable sensitivity and specificity when compared against a dietitian assessment, and 
is superior to serological analysis in predicting dietitian-rated adherence categories (Leffler et 
al., 2009). The Biagi GFD score (Biagi et al., 2009) and the Morisky Medication Adherence 
Scale (Morisky, Ang, Krousel-Wood, & Ward, 2008; Morisky, Green, & Levine, 1986), 
adapted to GFD adherence (Casellas et al., 2008) have also been proposed and undergone 
some psychometric evaluation, although neither have been validated against the gold 
standard. While measures that consider unintentional gluten exposure are an advancement 
over single-items that rely on accurate patient recall, truly reliable assessment of GFD 
adherence is difficult and remains a challenge in both research and clinical practice.  
Current guidelines on the management of CD (Ludvigsson et al., 2014; NICE, 2015) 
and other chronic physical health problems (NICE, 2009) specify that mild-to-severe 
depression and subclinical depressive symptoms should be recognised and treated. A 
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potential association between depression and GFD adherence in CD would therefore have 
important implications for the assessment and treatment of patients, including the goals of 
optimising adherence and both physical and psychological wellbeing. In this context, 
inadequate adherence may contribute to the development of depressive symptoms via 
physiological mechanisms (e.g., malabsorption of nutrients; Hallert, Astrom, & Sedvall, 
1982; Hallert, Astrom, & Walan, 1983; Hallert, Svensson, Tholstrup, & Hultberg, 2009). 
Conversely, the presence of depressive symptoms may limit an individual’s ability to achieve 
and maintain adequate adherence. Building on previous research in CD and informed by that 
in other chronic illnesses, the primary aim of this meta-analysis was to synthesise the 
available evidence on the relationship between reliably-measured GFD adherence (that is, 
where an attempt was made to assess unintentional gluten consumption) and either 
depression or depressive symptoms in adults with CD. The secondary aim was to summarise 
the available information on the direction of causation of any observed relationship. 
 
METHODS 
Eligibility criteria 
Studies were eligible for inclusion if they: (1) assessed the degree of adherence to a 
GFD using a method that considered unintentional gluten consumption, in adults (≥18 years) 
with treated CD (i.e., post-diagnosis and attempting a GFD; no specific criteria regarding 
duration of GFD was imposed); (2) used a validated symptom rating scale to assess 
depressive symptoms; or used a diagnostic interview or other valid method to assess 
clinically diagnosable depression; and (3) statistically reported the relationship between GFD 
adherence and depressive symptoms/depression. All group-based study designs (e.g., cross-
sectional, prospective, interventions) were eligible; inclusion was limited to studies published 
in English. Full-text published studies and those ahead of publication were eligible; 
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conference abstracts and dissertations were eligible if a full-text paper had not been 
published. Studies were excluded if they: (1) assumed strict adherence solely based on GFD 
duration; or (2) only included newly-diagnosed CD patients measured at baseline, as the 
degree of adherence cannot be assessed prior to GFD onset. Prospective studies of newly-
diagnosed patients were, however, eligible if, in addition to the baseline measurement, 
adherence and depression/depressive symptoms were measured again post-diagnosis/onset of 
the GFD.  
Based on current evidence for the adequacy of measurement of GFD adherence and 
need to capture unintentional consumption, studies that used the CDAT, the Biagi GFD 
score, the adapted Morisky scale, a dietitian-rated assessment (the gold standard), or a 
combination were eligible for inclusion. Studies that used an unreliable measure, such as a 
visual analogue or Likert scale assessing the perceived strictness of adherence or the 
frequency of (typically only intentional) gluten consumption, were excluded.  
Electronic searches 
Comprehensive systematic searches were conducted by the first author (KS) in 
February 2016 in PsycINFO, Web of Science, PubMed, Cinahl, and the Cochrane Library 
using the following search strategy: (coeliac disease OR celiac disease OR gluten free diet) 
AND (depression OR depressive symptoms). The reference lists of included papers and 
previous reviews (Smith & Gerdes, 2012; Zingone et al., 2015) were additionally hand-
searched for any relevant papers (KS).  
Study selection 
Following the manual removal of duplicates using Endnote (version X7.7; Clarivate 
Analytics, 2016), the first author (KS) completed the title screening. Articles retained at the 
abstract and full-text screening stages were independently double-screened and categorised as 
eligible/ineligible by both authors using a pre-specified eligibility form (which included 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 8 
information pertaining to each of the eligibility criteria: adequate measurement of GFD 
adherence and depressive symptoms/clinical depression in adults with diagnosis of CD, post-
diagnosis and attempting a GFD; statistically reported the relationship between depressive 
symptoms/depression and GFD adherence). Any disagreements were resolved through 
discussion between the two authors (KS, MM) until consensus was reached.  
Risk of bias 
Risk of bias was assessed for each study using accepted tools for cross-sectional study 
designs (National Institutes of Health, 2014; The Joanna Briggs Institute, 2016; Thomas, 
Ciliska, Dobbins, & Micucci, 2004). Items were adapted to the current question using pre-
decided criteria, and updated, as needed, after the two assessors (KS, MM) had independently 
rated and discussed the first three papers (alphabetically) until agreement was reached. The 
items assessed: (1) clearly defined study population and inclusion criteria; (2) the 
objective/standardised measurement of CD; (3) representativeness; (4) sample size; and (5) 
appropriate statistical analysis of the bivariate relationship between depressive symptoms and 
GFD adherence.  
Items assessing the validity/reliability of the outcome (GFD adherence) and exposure 
(depressive symptoms/depression) measures were not included in the quality assessment, as 
these formed part of the eligibility criteria; all included studies were therefore rated as having 
a low risk of bias for this domain. Note, that due to the absence of prior information on the 
direction of causation, outcome and exposure could equally have been defined as depressive 
symptoms and GFD adherence, respectively. Each item was rated as ‘very likely’ (low risk of 
bias), ‘somewhat likely’ (moderate), ‘not likely’ (high), or ‘not reported’ (unclear; see 
Supplementary material). Overall, studies were rated as having a high, moderate, low, or 
unclear risk of bias.  
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Risk of bias assessments were conducted independently by the two authors (KS, MM) 
and any discrepancies were resolved through discussion. Cohen’s kappa was used to calculate 
inter-rater agreement.  
Data extraction 
Extracted data included: (1) depressive symptoms/depression and GFD adherence 
measures; descriptive statistics for each; (2) sample size and characteristics of CD patients 
(e.g., demographics and GFD duration); (3) study design; (4) statistical estimate of the 
depressive symptoms/depression-GFD adherence relationship. If this relationship was not 
reported, or a total score rather than individual subscale scores (e.g., depressed mood 
subscale of the Psychological General Wellbeing Index) was reported, authors were 
contacted via email and sent a reminder after two weeks, if they had not responded. Data 
extraction was completed independently by both authors using a pre-specified form. Any 
disagreements were resolved through consensus discussion.  
Data synthesis 
Characteristics and findings of all the included studies were tabulated and statistical 
estimates were quantitatively combined in a meta-analysis using Comprehensive Meta-
Analysis (CMA; version 3; Biostat, 2016). To calculate effect sizes, the sample size and 
value of the bivariate correlation (Pearson’s product moment correlation; r) was extracted 
from the original articles. If not reported, effect sizes were computed in CMA based on the 
statistical estimators reported. Fisher’s z transformations were used to calculate the weighted 
average effect sizes (r+; all calculations were automatically conducted in CMA). Meta-
analyses were conducted using the random-effects model (Borenstein, Hedges, Higgins, & 
Rothstein, 2009), because a range of methods were used to assess both depressive symptoms 
and GFD adherence. These were interpreted according to Cohen’s guidelines (values of 
r=0.10, 0.30, and 0.50 correspond to weak, moderate, and strong effects respectively; Cohen, 
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1988). Z-values, 95% confidence intervals, and corresponding p-values indicated the 
significance of the association; standard residuals were also inspected for outliers (>1.96). 
Separate analyses were planned for studies measuring self-reported depressive symptoms and 
those measuring clinical depression. 
Heterogeneity in the effects was determined using: (1) Cochran’s Q statistic 
(Cochran, 1954), for which a significant effect (<0.10 when analysis includes a small number 
of studies) demonstrates heterogeneity between studies; and (2) the I2 statistic (Higgins, 
Thompson, Deeks, & Alman, 2003), which ranges from 0-100%, with values of 25%, 50%, 
and 75% reflecting low, moderate, and high heterogeneity respectively.  
A sensitivity analysis, in which studies rated as having a high, moderate, or unclear 
risk of bias were excluded, was conducted to determine the impact of risk of bias on the 
pooled effect size. Publication bias was examined by visually inspecting the funnel plot for 
evidence of asymmetry. The meta-analysis and systematic review reported here followed the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 
(Moher, Liberati, Tetzlaff, Altman, & PRISMA group, 2009). The review was registered in 
the PROSPERO register of systematic reviews (reference: CRD42016033711).  
RESULTS 
Study selection  
The systematic search identified 1158 potentially relevant papers for inclusion; after 
duplicates were removed, 641 papers underwent screening (see Figure 1 for PRISMA flow 
chart). Following title and abstract screening, 84 papers were retained for full-text screening, 
which resulted in 8 studies (reported in 9 papers) being included in the meta-analysis (Arigo, 
Anskis, & Smyth, 2012; Edwards-George et al., 2009; Kerswell & Strodl, 2015; Mahadev, 
Gardner, Lewis, Lebwohl, & Green, 2015; Nachman et al., 2009; Nachman et al., 2010; 
Sainsbury, Mullan, & Sharpe, 2013a, 2013b; Weiss et al., 2013). All 8 studies measured 
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depressive symptoms; no studies that measured clinically diagnosable depression and met 
other criteria were identified. The main reasons for exclusion at the full-text screening stage 
(see Supplementary material) were: did not measure depressive symptoms/depression and/or 
GFD adherence, or did the latter using an unreliable measure (e.g., Likert or visual analogue 
scale). Eight of the 75 excluded papers were eligible based on the measurement of depressive 
symptoms/depression and GFD adherence (dietitian interview: k=6; CDAT: k=1), but the 
data needed to assess the relationship of interest were not reported and authors did not 
respond to requests for additional information (k=6) or were unable to provide the data (k=2).   
Study characteristics 
The characteristics of included studies are presented in Table 1. Studies were 
published between 2009 and 2015, and included between 53 and 390 CD patients (total 
N=1644; median=188). Four studies were conducted in the USA (Arigo et al., 2012; 
Edwards-George et al., 2009; Mahadev et al., 2015; Weiss et al., 2013), three in Australia 
(Kerswell & Strodl, 2015; Sainsbury et al., 2013a, 2013b), and one in Argentina (one study 
published in two papers; Nachman et al., 2009; Nachman et al., 2010). Females were over-
represented in all samples (median=83.4% female; range=76.6-100%). The mean age of 
included participants ranged from 39-57 years (reported for 6 studies); one study reported the 
median age (47 years; Mahadev et al., 2015), and one did not report age (Nachman et al., 
2009; Nachman et al., 2010). When reported, participants were highly educated (47-93% had 
completed college/university education; 5 studies) and were usually in employment (~70% 
full-time or part-time; 4 studies).  
Only 4 studies reported the mean (range=4.6-6.8 years) or median (4 years) GFD 
duration (Edwards-George et al., 2009; Mahadev et al., 2015; Sainsbury et al., 2013a; 
Sainsbury et al., 2013b). The same 4 studies, and one additional study (Kerswell et al., 2015), 
reported the mean or median age at diagnosis, which ranged from 36 to 45 years. Comparison 
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of GFD duration with the difference between current age and age at diagnosis suggested that 
most participants commenced the GFD immediately upon diagnosis, although this was not 
reported separately in any of the studies.  
Seven studies used a cross-sectional design (Arigo et al., 2012; Edwards-George et 
al., 2009; Kerswell & Strodl, 2015; Mahadev et al., 2015; Sainsbury et al., 2013a, 2013b; 
Weiss et al., 2013). The remaining study was a prospective study with measurement at 
diagnosis and after 1- and 4-years on a GFD; the relationship of interest was analysed cross-
sectionally at both follow-up time points (Nachman et al., 2009; Nachman et al., 2010).  
GFD adherence and depressive symptoms 
Five studies measured GFD adherence using the CDAT (Kerswell & Strodl, 2015; 
Mahadev et al., 2015; Sainsbury et al., 2013a, 2013b; Weiss et al., 2013), two used a 
dietitian-rated assessment (Edwards-George et al., 2009; Nachman et al., 2009; Nachman et 
al., 2010), and one used the adapted Morisky adherence scale (Arigo et al., 2012). When 
reported, the mean scores for GFD adherence indicated that, on average, participants were 
highly adherent (Arigo et al., 2012; Edwards-George et al., 2009; Mahadev et al., 2015; 
Sainsbury et al., 2013a, 2013b). The proportion of each sample falling into the inadequate 
adherence range (21.4-43.4%) suggested lower rates of strict adherence though (Edwards-
George et al., 2009; Mahadev et al., 2015; Nachman et al., 2009; Nachman et al., 2010; 
Sainsbury et al., 2013a, 2013b). 
The Depression Anxiety Stress Scale was the most commonly used self-reported 
depression rating scale (Kerswell & Strodl, 2015; Sainsbury et al., 2013a, 2013b; Weiss et 
al., 2013). Other measures included the Beck Depression Inventory (Edwards-George et al., 
2009; Nachman et al., 2009; Nachman et al., 2010), the Depressed Mood subscale of the 
Psychological General Wellbeing Inventory (Mahadev et al., 2015), and the Centre for 
Disease Studies Depression Scale (Arigo et al., 2012). Mean scores for self-reported 
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depressive symptoms fell in the normal to minimal/mild range (Arigo et al., 2012; Mahadev 
et al., 2015; Nachman et al., 2009; Nachman et al., 2010; Sainsbury et al., 2013a, 2013b). 
Risk of bias assessment 
The risk of bias assessment is presented in Table 2. Inter-rater agreement was ‘almost 
perfect’ (Cohen’s kappa=0.958; Cohen, 1960). No major threats to study quality were 
apparent on the first two items: all except one study was clear in their description of the target 
population and inclusion criteria (item 1), and all attempted to ensure that included patients 
had a biopsy-confirmed, medical diagnosis of CD (item 2). This was done as part of the 
research procedure (Nachman et al., 2009; Nachman et al., 2010); or confirmed by patient 
self-report and/or assumed based on coeliac society membership (medical diagnosis required) 
or being listed in the clinic database (where the diagnosis was made).  
Representativeness (item 3) was deemed ‘very likely’ in two studies, based on 
recruitment invites being sent to a randomly-selected sample of eligible coeliac society 
members identified via a database screen (Sainsbury et al., 2013a, 2013b). All bar two of the 
remaining studies were rated as ‘somewhat likely’ for using multiple recruitment methods to 
reduce bias (Arigo et al., 2012; Edwards-George et al., 2009; Mahadev et al., 2015), or an 
attempt to demonstrate comparability with previous samples of CD patients (Kerswell & 
Strodl, 2015). The one non-cross-sectional (prospective) study included a representative 
sample at baseline, obtained using a consecutive enrolment approach in newly diagnosed 
patients (Nachman et al., 2009; Nachman et al., 2010), but was compromised by significant 
attrition at both follow-up time-points and lack of reporting on differences by drop-out status 
or an attempt to control for attrition in analyses, which reduced the rating to ‘not likely’. The 
final study (conference abstract only; Weiss et al., 2013) did not explicitly report details for 
criteria 1-3, although they could be partially inferred from the recruitment method (coeliac 
support group). Only two studies provided a power calculation (item 4; Arigo et al., 2012; 
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Sainsbury et al., 2013b), but all others met the minimum sample size according to criteria 
employed for the type of statistical analysis (i.e., 50 cases for a bivariate correlation, or 30 
cases per group when comparing two or more groups).  
Appropriate analyses (i.e., correlation/linear regression for continuously measured 
variables, or t-test/ANOVA/logistic regression/odds ratio for data involving one or both 
categorical variables; item 5) were used in all cases – reported in six papers and conducted by 
the review team for the two studies for which raw data was obtained from authors (Mahadev 
et al., 2015; Sainsbury et al., 2013b). Ratings of ‘somewhat likely’ for items 1-4 were 
deemed not to pose a major threat to study quality and were therefore viewed as equivalent to 
‘very likely’ for the purposes of summarising overall risk of bias. Six studies were rated as 
having a low risk of bias (Arigo et al., 2012; Edwards-George et al., 2009; Kerswell & Strodl, 
2015; Mahadev et al., 2015; Sainsbury et al., 2013a, 2013b); one study had a moderate risk of 
bias (Nachman et al., 2009; Nachman et al., 2010); and the other was rated unclear based on 
incomplete reporting (Weiss et al., 2013). 
Meta-analysis  
Effect sizes for five studies were extracted directly from the papers (Arigo et al., 
2012; Edwards-George et al., 2009; Kerswell & Strodl, 2015; Sainsbury et al., 2013a; Weiss 
et al., 2013). Raw data was obtained for two studies in which the relevant information was 
not reported (Mahadev et al., 2015; Sainsbury et al., 2013b) and the correlations were 
computed by the first author. In the final study (Nachman et al., 2009; Nachman et al., 2010), 
means and standard deviations on the depression rating scale for the strictly and partially 
adherent groups were extracted and entered into CMA, where the effect size was 
automatically computed. The primary meta-analysis was conducted using only the 4-year 
data (Nachman et al., 2010) from the study that provided 2 effect sizes, as this was deemed 
more comparable to the other studies on GFD duration.  
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The pooled effect size for the 8 included studies was r=0.398 (95% CI=0.321-0.469, 
z=9.355, p<.001; see Figure 2), based on a total sample size of 1644 participants. The study 
by Kerswell (Kerswell & Strodl, 2015) showed the strongest association between depressive 
symptoms and adherence (r=0.510), while the Edwards-George study (Edwards-George et 
al., 2009) showed the weakest association (r=0.250); all effect sizes were significant. 
Inspection of the standard residuals indicated no outliers. There was evidence of moderate 
heterogeneity between studies (Q=21.097, p=.004; I2=66.819).  
Sensitivity analysis and publication bias 
A sensitivity analysis excluding the two studies that were rated as having a moderate 
(Nachman et al., 2009; Nachman et al., 2010) or unclear risk of bias (Weiss et al., 2013) did 
not substantially change the results (r=0.394, 95% CI=0.303-0.477, z=7.887, p<.001).  
The small number of included studies also prevented the use of publication bias 
estimates (it is not recommended to test for publication bias with <10 studies; Sterne et al., 
2011), although visual inspection of the funnel plot did not reveal any asymmetry.  
DISCUSSION 
This meta-analysis represents the first attempt to synthesise the available evidence on 
the relationship between GFD adherence and depression/depressive symptoms in adult 
patients with CD. Only eight eligible studies were identified, all of which measured self-
reported depressive symptoms rather than the presence of a clinical diagnosis of depression, 
and reported cross-sectional analyses. Consistent with the hypothesis, the results showed that 
higher levels of self-reported depressive symptoms were moderately associated with poorer 
GFD adherence. The present findings are comparable with research in other illnesses (e.g., 
diabetes) and varying treatment regimens (e.g., medication, diet and physical activity 
recommendations), where it has been found that depression acts as a barrier to good 
adherence (DiMatteo et al., 2000; Gonzalez et al., 2008; Grenard et al., 2011).  
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In CD, there is a paucity of research assessing the relationship between clinically 
diagnosable depression and adequately measured GFD adherence. Two studies included in 
this meta-analysis additionally reported the proportion of CD patients with differing 
adherence levels who scored above the clinical cut-off indicative of depression on their 
respective questionnaires, albeit with contrasting results (Arigo et al., 2012; Nachman et al., 
2009; Nachman et al., 2010). One additional study was identified but could not be included 
due not reporting the relationship of interest (GFD adherence measured using the CDAT; van 
Hees, Giltay, Geleijnse, Janssen, & van der Does, 2014). More research is therefore needed 
to determine the impact of more severe manifestations of depression on GFD adherence and 
vice versa. Given the moderate-strength relationship between self-reported depressive 
symptoms and GFD adherence and the fact that, of those that reported this information, mean 
scores were suggestive of only low or mild levels of depressive symptoms, it seems likely 
that diagnosable depressive conditions would also show a relationship with worse GFD 
adherence.  
All but one of the included studies adopted a cross-sectional design, so it remains 
unclear whether depressive symptoms are the cause or consequence of poor adherence. The 
one study that utilised a prospective data collection protocol (Nachman et al., 2009; Nachman 
et al., 2010) unfortunately did not report any prospective analyses. Instead the data was 
analysed cross-sectionally within each time point, so it too was unable to contribute to 
answering the question of causation. Evidence suggests that gluten exposure in CD patients 
triggers a series of physiological mechanisms that are linked to the development of 
depression (e.g., deficiencies in vitamin B deficiency and serotonin metabolites; Hallert et al., 
1982; Hallert et al., 1983; Hallert et al., 2009). In the same way that a significant proportion 
of refractory CD cases (i.e., failure to achieve symptomatic and histological remission despite 
treatment with a GFD) are accounted for by unintentional gluten exposure, detected only with 
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rigorous methods (Abdulkarim, Burgart, See, & Murray, 2002), it may also be the case that 
ongoing consumption of trace amounts of gluten are responsible for the persistence of 
depressive symptoms in treated CD patients.  
The perception of an increased ability to maintain adherence, despite changes in mood 
and stress, has also been linked to better GFD adherence (Leffler et al., 2008). Similarly, CD 
patients do not differ in their intention to follow a strict GFD, but depressive symptoms 
appear to limit the translation of positive intention into strict adherence (Sainsbury et al., 
2013a). Together, these findings may suggest that under conditions of depression or low 
mood, some individuals with CD may be more prone to gluten-related lapses. Consistent with 
psychological theory (e.g., Kwasnicka, Dombrowski, White, & Sniehotta, 2016), this is likely 
due to a decrease in the usual level of vigilance and self-regulation (e.g., planning and 
monitoring) that occurs with low mood and that is required to maintain good adherence. This 
specific hypothesis, as well as the broader question of directionality, requires testing. 
Intentional gluten consumption appears to be less common (Hall et al., 2009; Hall, Rubin, & 
Charnock, 2013). More high-quality research, using prospective and longitudinal designs, is 
needed to provide a more definitive answer to the question of causality. 
Limitations and directions for future research 
The main limitation of this meta-analysis was the small number of eligible studies, 
which limited the power of the primary analysis and prevented the conduct of potential post-
hoc moderator and subgroup analyses to determine the impact of other variables (e.g., disease 
and/or methodological characteristics) on the relationship of interest. While the narrow 
inclusion criteria adopted here certainly contributed to this lack of power, only by assessing 
the degree of adherence in CD patients who have already commenced a GFD – rather than 
the problematic reliance on categorical distinctions (e.g., on a GFD vs. yet not started a GFD) 
– and by excluding studies with inadequate measurement of adherence, can the question of 
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interest be answered. In support of the latter point, none of the five studies that were excluded 
based on unreliable measurement of GFD adherence (i.e., Likert or visual analogue scales 
assessing the frequency of gluten consumption) found a significant relationship with 
depressive symptoms (Barratt, Leeds, & Sanders, 2011; Ciacci, Iavarone, Mazzacca, & De 
Rosa, 1998; Ford, Howard, & Oyebode, 2012; Hauser, Janke, Klump, Gregor, & Hinz, 2010; 
van Hees, Van der Does, & Giltay, 2013).  
Regarding publication bias, although there was no evidence of asymmetry in the 
visual inspection of the funnel plot, this could not be tested formally (e.g., using Egger’s test) 
due to the small number of studies (less than 10 studies were included; Sterne et al., 2011). 
The eight studies that were eligible based on having measured the two constructs of interest 
but were excluded as the statistical relationship between them was not reported, may have 
altered the pattern observed here. It therefore cannot be ruled out that the inclusion of a larger 
number of studies would have changed the results or led to the identification of real 
asymmetries in the data.  
There was significant heterogeneity in the effects between studies, which may be 
accounted for by potential moderators. As stated previously, the conduct of moderator 
analyses was not feasible here due to the limited number of studies meeting inclusion criteria. 
Previous literature and the characteristics observed in the included studies do, however, 
suggest that the following variables may worthy candidates for investigation in future 
research. Despite the known gender imbalance in CD diagnoses (male: female ratio of 1:2-3; 
Green et al., 2001), more than half the studies recruited ≥80% females (Arigo et al., 2012; 
Kerswell & Strodl, 2015; Nachman et al., 2009; Nachman et al., 2010; Sainsbury et al., 
2013a, 2013b; Weiss et al., 2013), suggesting an additional gender bias that warrants further 
consideration. In contrast, the included samples appeared representative of the known CD 
population regarding age of diagnosis (Green & Jabri, 2006). Adjustment to the diagnosis and 
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the GFD could, however, plausibly differ according to both age of diagnosis and duration of 
GFD, suggesting that these variables may also moderate the adherence-depression 
relationship. CD patients with comorbid IBS-type symptoms (Hauser, Musial, Caspary, Stein, 
& Stallmach, 2007), diabetes and autoimmune conditions (Garud et al., 2009), and elevated 
thyroid anti-bodies (Carta et al., 2002), have higher rates of depression than patients with CD 
alone, suggesting that controlling for the presence of comorbidities may also help to explain 
differences in effects. Representativeness and recruitment or selection bias are common 
problems in CD research, and it is possible that differences in motivation and dietary 
vigilance exist according to membership of a coeliac society (Hall et al., 2009), which may 
change the results if more diverse recruitment methods were used. Methodologically, it also 
possible that the diverse measures (self-reported questionnaire versus interview-based) used 
to assess both depressive symptoms/depression and GFD adherence impacted the results, and 
attention should be given to study and measurement issues in future research.  
Finally, the lack of prospective and longitudinal study designs is a clear limitation in 
the literature and prevented any descriptive or statistical analyses from being conducted to 
achieve the second aim of this review. This means that the direction of causation between 
depressive symptoms and GFD adherence remains unclear. Future research, using more 
rigorous designs and reliable measurement, is needed to achieve clarity on this point. To gain 
a comprehensive understanding of the full spectrum of factors that may impact the 
relationship between depression and adherence, a synthesis of the existing literature on the 
variables that predict either depression/depressive symptoms or GFD adherence in CD 
patients is needed.  
Conclusion 
The existing evidence for a relationship between depressive symptoms and/or 
depression and GFD adherence in adults with CD is limited. Nonetheless, what is available 
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suggests a moderate-strength relationship. From a clinical point of view, regardless of the 
additional factors that may be implicated in the relationship and its direction, identification 
of, and support to improve, poor adherence and depression/depressive symptoms in CD 
should be considered to reduce the burden of illness associated with deficiencies in both 
physical and mental health. Based on these tentative findings, there may be a role for 
psychological services in addition to dietetic input in the ongoing management and follow-up 
of GFD adherence for affected CD patients (Ludvigsson et al., 2014; NICE, 2015), even in 
cases of low-level, subclinical depressive symptoms (NICE, 2009). Online and face-to-face 
interventions using both individual and group-based formats have shown promise in 
improving GFD adherence and psychological wellbeing in CD (Addolorato et al., 2004; Ring 
Jacobsson, Friedrichsen, Goransson, & Hallert, 2012; Sainsbury, Mullan, & Sharpe, 2013c), 
and could help to achieve needed improvements in both directions.   
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Table 1. Characteristics of included studies (k = 8) 
Study  Study design N, % female, 
mean age, 
education and 
employment 
Type of CD patients, 
mean GFD duration, 
age at diagnosis, 
recruitment  
GFD adherence 
measure and results  
Depression 
measure and 
results  
Relationship between GFD 
adherence and depression 
Arigo et al. 
(2012)  
 
Cross-sectional N = 177 
100% female 
Age = 39.24 
Education and 
employment 
not reported 
Unselected CD 
patients; GFD 
duration/age at 
diagnosis not 
reported; recruited via 
CD organisations, 
online support 
networks, and online 
newsletters 
Morisky Medication 
Adherence Scale, 
adapted for GFD 
adherence (M = 4.47, 
SD = 1.06; maximum 
possible score of 5; 
higher scores indicate 
better adherence)  
 
 
Centre for Disease 
Studies – 
Depression Scale 
(M = 14.96, SD = 
10.9; higher scores 
indicate worse 
depression) 
Higher depression scores 
were associated with poorer 
GFD adherence (r = -0.28, p < 
.01); women who scored at 
or above the clinical cut-off 
for depression reported 
poorer GFD adherence (M = 
4.29, SD = 1.26) than women 
who scored below the cut-off 
for depression (M = 4.63, SD 
= 0.82, t = 2.12, p < .05). 
Edwards-
George et 
al. (2009) 
 
Cross-sectional 
 
N = 154 
76.6% female 
Age = 50.35 
Education: 
68% had a 
bachelor’s 
degree or 
higher 
Employment: 
70% full time 
or part time 
 
CD patients on a GFD 
for at least 3 months; 
GFD duration (mean) = 
4.9 years; age at 
diagnosis = 44.79; 
recruited via clinic 
appt.’s, flyer mailed to 
patients who had 
previously attended 
clinic, local CD support 
groups, and CD 
newsletters 
 
Expert dietitian 
evaluation (analysis of 
3-day food records, 
food ingredient quiz, 
and a clinical 
interview) (M = 1.92, 
SD = 1.12; observed 
range = 1-6, higher 
scores indicate poorer 
adherence; 44.2% 
excellent adherence: 
34.4% good; 21.4% 
inadequate) 
BDI-II (no 
descriptive 
statistics reported; 
higher scores 
indicate worse 
depressive 
symptoms) 
Higher levels of non-
adherence were associated 
with higher depression scores 
(r = 0.25, p = .002); 
depression was not a 
significant independent 
predictor of adherence 
(dichotomised into good vs. 
inadequate) in a logistic 
regression model. 
 
Kerswell & 
Strodl 
(2015) 
 
Cross-sectional N = 253 
91.4% female 
Age = 42.34 
Education: 
Unselected CD 
patients; GFD duration 
not reported; age at 
diagnosis = 35.72; 
CDAT (no descriptive 
statistics reported; 
higher scores indicate 
poorer adherence) 
DASS (no 
descriptive 
statistics reported; 
higher scores 
Higher depression scores 
were associated with poorer 
adherence (r = 0.51, p < 
.003). 
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58% 
undergraduate 
or post-
graduate 
degree 
Employment: 
69% full time 
or part time 
 
recruited via coeliac 
society (Facebook 
page and monthly 
online newsletter) 
indicate worse 
depressive 
symptoms) 
Mahadev et 
al. (2015) 
 
Cross-sectional N = 211 
78% female 
Age (median) 
= 47  
Education: 
93% college or 
graduate 
school 
Employment 
not reported 
 
 
Screen- and symptom-
detected CD patients; 
GFD duration (median) 
= 4 years; age at 
diagnosis = 39; 
recruited via clinic 
appt.’s, patient 
support conferences, 
and mail/email invites 
sent to patients in the 
clinic database 
 
CDAT (M = 12.0, SD = 
3.9; observed range = 
7-25; higher scores 
indicate worse 
adherence; 55.5% 
excellent or very good; 
26.1% moderate; 9.5% 
fair to poor) 
PGWB – depressed 
mood subscale (M 
= 15.7, SD = 2.8; 
observed range = 
5-18, higher scores 
indicate less severe 
depressive 
symptoms) 
Higher depression scores 
were associated with poorer 
adherence (r = -0.473, p < 
.001). 
Nachman et 
al. (2009)/ 
Nachman et 
al. (2010) 
 
Repeated 
measurement 
in same CD 
participants 
(depressive 
symptoms-
adherence 
relationship 
analysed cross-
sectionally) 
2009 (1-year): 
N = 84 
84% female  
Age, 
education, and 
employment 
not reported 
  
2010 (4-
years): N = 53 
90.6% female 
Age, 
Newly diagnosed CD 
patients assessed after 
1-year and 4-years on 
a GFD; age at 
diagnosis not 
reported; 
consecutively 
enrolled/recruited at 
diagnosis from clinic 
Combination of 
dietitian interview, 
opinion of treating 
physician, 4-day food 
diary, and patient self-
report (1-year: 70.2% 
strict adherence, 
29.8% partial 
adherence; 4-years: 
50.9% strict, 49.1% 
partial) 
BDI (higher scores 
indicate worse 
depressive 
symptoms) 
1 year: Depression scores did 
not differ between the CD 
patients who were strictly 
adherent (M = 7.9, 95% CI = 
4.8-11.0) and those who 
were partially adherent (M = 
6.3, 95% CI = 3.6-9.5; p = ns; r 
= 0.068, p = 0.532). 
 
4 years: Partially adherent CD 
patients (M = 11.3, 95% CI = 
7.6-15) had significantly 
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education, and 
employment 
not reported 
 
higher depression scores than 
CD patients with strict GFD 
adherence (M = 5.8, 95% CI = 
2.1-9.5, p = 0.03; r = 0.278, p 
= .034). There was no 
difference in the proportion 
of CD patients scoring above 
the clinical cut-off for 
depression according to 
adherence category (strict vs. 
partial).  
Sainsbury et 
al. (2013a) 
 
Cross-sectional N = 390 
82.8% female 
Age = 44.2 
Education: 
57% 
undergraduate 
or post-
graduate 
degree 
Employment: 
70% full time 
or part time/ 
casual 
 
CD patients, on a GFD 
for at least 3 months; 
GFD duration (mean) = 
6.8 years; age at 
diagnosis = 37.4; 
recruited via coeliac 
society (email sent to 
randomly selected 
members meeting the 
inclusion criteria, 
based on database 
screening) 
CDAT (M = 12.31, SD = 
3.17; observed range = 
7-31, higher scores 
indicate poorer 
adherence; 56.7% 
excellent or very good; 
37.2% moderate; 6.2% 
fair to poor) 
DASS (M = 6.2, SD = 
8.2; observed 
range = 0-42, 
higher scores 
indicate worse 
depression) 
Higher depression scores 
were associated with poorer 
adherence (r = 0.33, p < 
.001). 
Sainsbury et 
al. (2013b; 
study 2 
only) 
 
Cross-sectional 
(baseline 
relationships in 
a sample of CD 
patients 
enrolled in an 
intervention to 
improve GFD 
N = 189 
87.3% female 
Age = 46.5 
Education: 
47% 
undergraduate 
or post-
graduate 
CD patients, on a GFD 
for at least 3 months; 
GFD duration (mean) = 
4.6 years; age at 
diagnosis = 42.1; 
recruited via coeliac 
society (email sent to 
randomly selected 
CDAT (M = 12.2, SD = 
3.44; observed range = 
7-28, higher scores 
indicate poorer 
adherence; 58.9% 
excellent or very good; 
33.2% moderate; 7.9% 
fair to poor) 
DASS (M = 5.9, SD = 
7.4; range = 0-42; 
higher scores 
indicate worse 
depression) 
Higher depression scores 
were associated with poorer 
adherence (r = 0.477, p < 
.001). 
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adherence) Employment: 
69% full time 
or part time/ 
casual 
 
members meeting the 
inclusion criteria, 
based on database 
screening) 
Weiss et al. 
(2013) 
 
Cross-sectional N = 186 
79.6% female 
Age = 56.5 
Education and 
employment 
not reported 
Unselected CD 
patients; GFD 
duration/age at 
diagnosis not 
reported; recruited via 
GFD support group (no 
details provided) 
CDAT (no descriptive 
statistics reported) 
DASS (no 
descriptive 
statistics reported) 
Higher depression scores 
were associated with poorer 
adherence (r = 0.48, p < 
.001). 
Note: CD = coeliac disease; GFD = gluten free diet; CDAT = coeliac dietary adherence test; BDI = Beck Depression Inventory; DASS = Depression, Anxiety, 
Stress Scale; PGWB = Psychological General Wellbeing Index 
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 Table 2. Risk of bias assessment 
Study Population/ 
inclusion 
Objective criteria 
for CD 
Representativeness Sample size Statistical 
analysis 
Overall risk of 
bias 
Arigo (2012) VL SL SL VL VL Low 
Edwards-George (2009) VL SL SL SL VL Low 
Kerswell (2015) VL SL SL SL VL Low 
Mahadev (2015) VL SL SL SL NR
#
 Low 
Nachman (2009, 2010) VL VL NL* SL VL Moderate  
Sainsbury (2013a) VL SL VL SL VL Low  
Sainsbury (2013b) VL SL VL VL~ NR
#
 Low  
Weiss (2013) NR NR NR SL VL Unclear  
VL = very likely; SL = somewhat likely; NL = not likely; NR = not reported  
* Not likely rating based on significant attrition from baseline to both 1-year and 4-year follow-up, a lack of details reported on differences between drop-
outs and those who remained in the study, and failure to account for attrition in follow-up analyses (i.e., per-protocol analysis rather than intention-to-
treat)  
~ Power analysis reported in linked paper on same sample (randomised controlled trial of behavioural intervention to improve GFD adherence; Sainsbury, 
Mullan, & Sharpe, 2013c) 
# Statistics for the relationship between depressive symptoms and GFD adherence were not reported – raw data obtained from study authors and analyses 
conducted by first author 
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Records identified through 
database searching (n = 1150) 
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Additional records identified 
through other sources  
(n = 8) 
Records after duplicates removed  
(n = 641) 
Records screened  
(n = 641) 
Records excluded  
(n = 557) 
Full-text articles assessed 
for eligibility  
(n = 84) 
Full-text articles excluded, 
with reasons (n = 75): did 
not measure GFD 
adherence (n = 32); 
unreliable GFD adherence 
measure (n = 15); did not 
measure depression/ 
depressive symptoms (n = 
14); depression-GFD 
adherence relationship not 
reported and no response 
from authors (n = 8); same 
sample as an already 
included paper (n = 3); 
design not suitable (n = 3) 
 
Studies included in 
qualitative synthesis (n = 8, 
reported in 9 papers) 
(n = 9) 
Studies included in 
quantitative synthesis (meta-
analysis: n = 8, reported in 9 
papers) 
Figure 1. PRISMA flow chart  
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Figure 2. Meta-analysis of the relationship between depressive symptoms and GFD adherence  
Note: Nachman et al., 2010 (assessment at 4-years post-diagnosis and GFD onset) was included rather than 
Nachman et al., 2009 (assessment at 1-year post-diagnosis and GFD onset) due to similarity with other 
included studies on GFD duration (mean/median > 4 years).  
